Trial · NCT04346888
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline to Day 43 | 43 days | The MG-ADL profile provides an assessment of MG symptom severity and measures 8 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the ADL score. The ADL score can range from 0 (least severe) to 24 (most severe) |
| Secondary | Change in the Myasthenia Gravis Composite (MGC) score from baseline to Day 43 | 43 days | The total QMG score is obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. |
| Secondary | Change in the Quantitative Myasthenia Gravis (QMG) score from baseline to Day 43 | 43 days | The QMG test is a standardized quantitative strength scoring system and measures 13 items on a 0-3 scale, with 0 being the least severe. The total sum of the 13 items represents the QMG score. The QMG score can range from 0 (least severe) to 39 (most severe). |
| Secondary | Change in the Myasthenia Gravis Quality of Life 15(MG-QoL15r) score from baseline to Day 43 | 43 days | The MG-QoL 15r scale is a patient-reported score that assesses the patient's perception of impairment and disability and the degree to which the patient tolerates disease manifestations. Each question was graded on a 3-point scale from 0=normal to 2=severe with a score of 0 to 30; the higher score indicates worse MG disease activity |
| Secondary | Proportion of participants with a decrease on the MG-ADL Score by ≥ 2 points from baseline to Day 43 | 43 days | |
| Secondary | Proportion of participants with an improvement and worse on the MGFA Post-intervention Status (MGFA-PIS) from baseline to Day 43. o Improvement: MGC Score reduce ≥ 3 points o Aggravation: MGC Score increase ≥ 3 points | 43 days | |
| Secondary | Change in the MG-ADL score from baseline to Day 120 | 120 days | |
| Secondary | Change in the MGC score from baseline to Day 120 | 120 days | |
| Secondary | Change in the QMG score from baseline to Day 120 | 120 days | |
| Secondary | Change in the MG-QoL15r score from baseline to Day 120 | 120 days | |
| Secondary | Proportion of participants with persistent improvement on the MGC score from baseline to Day 120 | 120 days | Improvement (decrease) in the MGC score by ≥ 3 points for 6 weeks |
| Secondary | Proportion of participants with persistent improvement on the MG-ADL score from baseline to Day 120 | 120 days | Improvement (decrease) in the MG-ADL Score by ≥ 2 points for 6 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04346888/registered